Outlook Therapeutics, Inc. has received notification from Nasdaq confirming that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, resolving a potential delisting issue.
Key Details
- Compliance Confirmation: Nasdaq notified the company on June 26, 2026, that the matter is now closed.
- Requirement Met: The company's common stock maintained a closing bid price of $1.00 or greater for ten consecutive business days, from June 11, 2026, to June 25, 2026.
- Listing Rule: This satisfies Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.